Related by context. All words. (Click for frequent words.) 65 HQK 63 ALN TTR 63 histone deacetylase HDAC inhibitor 62 mertansine 61 angiogenesis inhibitor 61 humanized monoclonal antibody 61 CEQ# 61 Plicera 61 Phase Ib study 61 orally bioavailable 61 DB# [003] 61 obatoclax 61 vidofludimus 61 GW# [003] 61 vascular disrupting agent 61 Omacetaxine 60 RhuDex ® 60 JAK2 inhibitor 60 HuMax CD4 60 HGS# 60 stated Michelle Berrey 60 targeted antifolate 60 Traficet EN 60 Janus Kinase 60 MEK inhibitor 60 volociximab 60 nucleoside analog 60 IgG1 antibody 60 YONDELIS 60 IAP inhibitor 60 vinca alkaloid 60 PSMA ADC 60 HuMax EGFr 59 receptor tyrosine kinase inhibitor 59 Debio 59 Archexin 59 darinaparsin ZIO 59 gamma secretase inhibitor 59 PRLX # 59 cannabinor 59 liposomal formulation 59 CRLX# 59 orally administered inhibitor 59 radiolabeled monoclonal antibody 59 vascular disrupting agents 59 PDE4 inhibitor 59 novel vascular disrupting 59 renin inhibitor 59 baminercept 59 pertuzumab 59 PI3K/mTOR 59 Lixivaptan 59 BrachySil TM 59 systemically administered 59 Factor VIIa 59 ATL# [001] 59 preclinical efficacy 59 depsipeptide 59 nucleotide analog 59 Phase Ib II 59 TRO# 59 Phase 1a clinical 59 Blinatumomab 59 histone deacetylase inhibitor 59 Aclidinium 58 PRTX 58 Fx #A 58 Ceflatonin R 58 metastatic hormone refractory 58 CCR5 antagonist 58 proteasome inhibitor 58 docetaxel Taxotere R 58 phase IIa clinical 58 fosbretabulin 58 JAK1 58 antibody MAb 58 CTAP# Capsules 58 INCB# [001] 58 polymerase inhibitor 58 metaglidasen 58 PI3K inhibitor 58 intranasal formulation 58 Phase Ib clinical 58 multi kinase inhibitor 58 ADP receptor antagonist 58 bortezomib Velcade 58 CCX# B 58 CCR9 antagonist 58 ONX 58 pan HDAC inhibitor 58 tumor vascular disrupting 58 IRX 2 58 relapsing multiple sclerosis 58 selective inhibitor 58 Phase IIIb clinical 58 SYN# 58 RNAi therapeutic targeting 58 Symadex 58 phase IIa 58 humanized anti 58 Panzem R NCD 58 randomized controlled Phase 58 RH1 58 PD LID 58 forodesine 58 BAY #-# 58 novel histone deacetylase 57 ENMD # 57 Squalamine 57 ulimorelin 57 Daclizumab 57 inhibitor RG# 57 selective agonist 57 AEG# 57 AKT inhibitor 57 PEG SN# 57 Myelodysplastic Syndrome MDS 57 OHR/AVR# 57 Sapacitabine 57 multicenter Phase II 57 chimeric monoclonal antibody 57 thalidomide Thalomid 57 Annamycin 57 Tesetaxel 57 Phase 2a trial 57 BIM #A# 57 multiple myeloma MM 57 Kinase Inhibitor 57 TH# [003] 57 oncolytic vaccine 57 selective kinase inhibitor 57 PKC# 57 Hsp# Inhibitor 57 relapsed refractory multiple myeloma 57 huN# DM1 57 Phase IIb clinical trials 57 PEGylated interferon beta 1a 57 Tyrima 57 anticancer agent 57 HepDirect prodrug 57 BENLYSTA ® 57 TG# [003] 57 EGFR HER2 57 Quinamed 57 HuLuc# 57 Sym# 57 JAK#/JAK# 57 MTP inhibitor 57 TG MV 57 oral prodrug 57 TRC# 57 Proxinium TM 57 Tasimelteon 57 cilengitide 57 alvespimycin 57 chemokine receptor 57 subcutaneous formulation 57 Phase #b/#a 57 recurrent glioblastoma 57 CCX# 57 Anti VEGF 57 essential thrombocythemia ET 57 reversible inhibitor 56 PRT# 56 antisense inhibitor 56 mitogen activated ERK kinase 56 TLR9 agonist 56 Enzastaurin 56 advanced hepatocellular carcinoma 56 XL# XL# 56 Anticalin ® 56 small molecule tyrosine 56 relapsed multiple myeloma 56 CYT# potent vascular disrupting 56 Bezielle 56 TMC# [002] 56 Litx 56 erlotinib Tarceva ® 56 antitumoral 56 BAL# [002] 56 imatinib Gleevec ® 56 murine monoclonal antibody 56 HSP# inhibitor 56 Gleevec resistant 56 Imprime PGG 56 Vidofludimus 56 fluticasone furoate 56 potently inhibited 56 Panzem R 56 EndoTAG TM -1 56 Cimzia TM 56 eniluracil 56 Phase IIa trials 56 Phase IIa trial 56 humanized monoclonal 56 anticancer compound 56 Kahalalide F 56 investigational humanized monoclonal antibody 56 Cloretazine R 56 HCV protease inhibitor 56 phosphatidylserine PS targeting 56 initiate Phase 1b 56 SRT# [003] 56 IMA# 56 sJIA 56 brivaracetam 56 elacytarabine 56 CRx 56 assessing T DM1 56 Aplidin 56 CBLC# 56 Phase 2a clinical 56 axitinib 56 generation purine nucleoside 56 PF # [002] 56 acting muscarinic antagonist 56 Vicinium TM 56 relapsing remitting multiple sclerosis 56 docetaxel Taxotere ® 56 Exherin TM 56 ATL/TV# 56 antisense inhibitors 56 Aplidin R 56 tanespimycin 56 protein tyrosine phosphatase 1B 56 potent antiproliferative 56 Bruton tyrosine kinase Btk 56 Eniluracil 56 OMNARIS HFA 56 dasatinib Sprycel ® 56 highly selective inhibitor 56 dose escalation trial 56 IAP inhibitors 56 PNP inhibitor 56 SIR Spheres 56 selectively inhibits 56 PI3K/Akt pathway inhibitor 56 TRX1 56 pain palliation 56 metastatic colorectal carcinoma 56 immunomodulator 56 EGS# 56 selective antagonist 56 Pathway Inhibitor 56 Xanafide 55 diabetic nephropathy 55 DEB# 55 P2Y 55 JAK inhibitors 55 Glypromate 55 Monoclonal antibody 55 GAMMAGARD 55 mGluR2 NAM 55 vWF 55 isoform selective 55 diabetic neuropathic pain 55 SAR# [004] 55 ATTR 55 elotuzumab 55 Phase 1b 55 lipopeptide 55 metastatic malignant 55 R#/MEM # 55 seliciclib CYC# 55 Yondelis ® 55 cathepsin K inhibitor 55 novel anticancer 55 photoprotective drug 55 Alvesco R 55 prostate cancer HRPC 55 mTOR inhibitor 55 BCR ABL inhibitor 55 xanthine oxidase inhibitor 55 HDACi 55 signal transduction inhibitor 55 YONDELIS R 55 CIPN 55 Mipomersen 55 Natalizumab 55 pharmacokinetic PK study 55 CCR2 55 aurora kinase 55 Cloretazine ® 55 hour bronchodilation 55 evaluating tivozanib 55 opioid induced bowel dysfunction 55 antiproliferative activity 55 Pertuzumab 55 LUMINATE 55 immunomodulatory therapy 55 paclitaxel poliglumex 55 diarrhea predominant irritable 55 VEGF receptor 55 Ceflatonin 55 adult chronic ITP 55 teriflunomide 55 lintuzumab SGN 55 lorvotuzumab mertansine 55 Phase 2b trial 55 thyroid hormone receptor 55 Janus kinase 55 SCH # 55 HepaSphere 55 Aviptadil 55 EVIZON 55 bortezomib Velcade R 55 TRX# 55 targeting CD# 55 Talabostat 55 Anavex #-# 55 LB# [003] 55 CIMZIA TM 55 Phase #b/#a clinical 55 topical ophthalmic 55 beta 1a 55 HoFH 55 telomerase activator 55 dose escalation clinical 55 XL# [003] 55 gemcitabine Gemzar ® 55 trodusquemine 55 Carfilzomib 55 HCV protease 55 resolvin 55 Onconase 55 vivo preclinical 55 AQ4N 55 TPI ASM8 55 ISIS # 55 INSPIRE Trial Phase III 55 accumulate preferentially 55 kinase inhibitor 55 ZD# [001] 55 INT# [002] 55 alagebrium 55 alpha folate receptor 55 perifosine KRX 55 oral ridaforolimus 55 Aflibercept 55 KSP inhibitors 55 HCD# [002] 55 hyperphenylalaninemia HPA due 55 NP2 Enkephalin 55 sodium glucose cotransporter 55 Virulizin ® 55 JAK inhibitor 55 somatostatin analog 55 OZURDEX ® 55 antitumor activity 55 MELAS 55 IIa trials 55 A1PI 55 sorafenib Nexavar 55 unresectable stage 55 pomalidomide 55 multikinase inhibitor 55 PEGylated interferon 55 Ataluren 55 FVIIa 55 Insegia 55 oral proteasome inhibitor 55 acting inhaled anticholinergic 55 romidepsin 55 Initiate Phase 55 non nucleoside 55 CD# CEA 55 Interferon alfa 55 long acting muscarinic 55 MAGE A3 ASCI 55 Dacogen decitabine 55 trabectedin 55 inhaled liposomal ciprofloxacin 55 glucokinase activator 55 activin receptor type 55 entinostat 55 CA4P 55 ISTODAX 55 2 inhibitor CYT# 55 ARG# 55 RhuDex R 55 rFIXFc 55 Phase 1b trial 55 lymphoid malignancies 55 Ambrisentan 55 RNA antagonists 55 tyrosine kinase inhibitor 55 recurrent NSCLC 55 oral tyrosine kinase 55 PSN# [001] 55 novel prodrug 55 ErbB2 positive 55 CIMZIA ™ 55 anti fibrotic 55 R roscovitine 55 amifampridine phosphate 54 Guanilib 54 humanised antibody 54 FK# 54 familial amyloidotic polyneuropathy FAP 54 peptidomimetic 54 adecatumumab MT# 54 Critical Limb Ischemia CLI 54 Alfimeprase 54 novel oral anticoagulant 54 Alfacell proprietary ribonuclease 54 Icatibant 54 phosphorothioate 54 Tarvacin TM 54 Enkephalin 54 metastatic renal cell carcinoma 54 gemcitabine carboplatin 54 Olaparib 54 Hsp# inhibitor 54 OncoVex 54 antisense oligonucleotide 54 humanised monoclonal antibody 54 methionine aminopeptidase 54 NVA# 54 Amigal 54 poly ADP ribose polymerase 54 oral renin inhibitor 54 drug zotarolimus 54 Pharmacokinetics PK 54 lumiliximab 54 CYT# 54 Kamada AAT 54 tumor xenograft models 54 phase IIb clinical 54 Hsp# inhibitors 54 M1 muscarinic 54 phase IIb study 54 phase IIb trial 54 PEG IFN 54 KSP inhibitor 54 TEMODAL 54 LymphoStat B TM 54 IIa trial 54 CD# antibody [001] 54 antimitotic 54 GHRH 54 OXi# 54 Tarvacin 54 VAPRISOL 54 Certolizumab pegol 54 Phase 1a 54 PrevOnco ™ 54 OMP #M# 54 PDE4 54 otelixizumab 54 PGL# 54 lupus nephritis 54 Phase Ib 54 oropharyngeal candidiasis 54 metastatic CRC 54 ProLindac TM 54 anti EGFR antibody 54 HCV polymerase 54 tubulin inhibitor 54 fistulizing Crohn disease 54 refractory NSCLC 54 omacetaxine mepesuccinate 54 IMC #B 54 Anticalin R 54 potently inhibit 54 epothilones 54 ARRY # 54 bendamustine 54 LymphoStat B belimumab 54 NXL# 54 selective adenosine 54 torezolid phosphate 54 DU #b 54 Angiotensin Converting Enzyme 54 TG# [001] 54 TACI Ig 54 CG# [003] 54 SGLT 54 Amrubicin 54 administered subcutaneously 54 null responder HCV 54 RAV# 54 Laquinimod 54 APOPTONE 54 vinorelbine tartrate 54 Liposomal 54 Pemetrexed 54 novel immunotherapeutic 54 HDAC Inhibitor 54 Dalbavancin 54 cetuximab Erbitux ® 54 oral FTY# 54 ARIKACE ™ 54 dose escalation Phase 54 refractory CLL 54 Genz # 54 retaspimycin hydrochloride 54 Vascular Disrupting Agent 54 liposomal doxorubicin 54 regorafenib 54 BLyS specific 54 Trophos 54 acid phosphatase PAP 54 MNTX 54 ACOMPLIA R 54 adenosine A2A 54 omacetaxine 54 CR# vcMMAE 54 mTOR inhibitors 54 posaconazole 54 prostanoid 54 sunitinib malate 54 investigational antiplatelet 54 multitargeted 54 demonstrated antitumor activity 54 topically administered 54 dose cohort 54 Fenretinide 54 FRDA 54 potent suppressor 54 Phase 2a Clinical Trial 54 adult mesenchymal stem 54 oral antiviral 54 favorable pharmacokinetic profile 54 BN# [004] 54 Phase IIa clinical 54 pharmacodynamic PD 54 registrational trial 54 MT# MEDI 54 Phase 2b clinical trials 54 ghrelin antagonist 54 castrate resistant prostate cancer 54 NS5A 54 1α 54 Tarceva TM 54 TELINTRA 54 radiation sensitizer 54 uricase 54 VEGF inhibitors 54 Fc fusion protein 54 lanreotide 54 ACV1 54 antiapoptotic 54 PSN# [002] 54 Safinamide 54 Actilon 54 Dasatinib 54 ISF# 54 AEGR 54 xenograft models 53 metastatic colorectal 53 Orally administered 53 monoclonal anti 53 DPP4 inhibitor 53 thymalfasin 53 ZOLINZA 53 RTP #i 53 #mg QD [002] 53 binds selectively 53 Nexavar sorafenib 53 Phase 2b study 53 HCV polymerase inhibitor 53 CLL SLL 53 corticosteroid dexamethasone 53 XL# XL# XL# 53 cell lymphoma CTCL 53 BRIM2 53 Alocrest 53 selective androgen receptor modulator 53 PEG Interferon lambda 53 refractory metastatic colorectal cancer 53 Qutenza TM 53 pulmonary arterial hypertension PAH 53 JAK3 53 ELACYT 53 papillary renal cell carcinoma 53 Irinotecan 53 Cimzia ® certolizumab pegol 53 selectively binds 53 Respiratory Viral Infections 53 Increlex R 53 Romidepsin 53 Imatinib mesylate 53 Elvitegravir 53 Phase IIb trials 53 Hervé Hoppenot President 53 erythropoietic 53 Phenoptin 53 GFT# 53 Allovectin 7 53 ganetespib 53 Enzyme Replacement Therapy 53 samalizumab 53 eltrombopag 53 riociguat 53 AVONEX ® 53 Kepivance 53 cystinosis patients 53 deforolimus 53 AZILECT ® 53 gallium containing 53 EORTC 53 tezampanel NGX# 53 RP# [002] 53 LUX Lung 53 rhIL 7 53 uremic pruritus 53 Nanobody 53 disease modifying 53 rNAPc2 53 opioid induced constipation 53 heavily pretreated 53 DCVax ® Brain 53 haematologic malignancies 53 antiangiogenic agent 53 Affimed Therapeutics AG 53 Glatiramer acetate 53 P#Y# [002] 53 epothilone 53 sargramostim 53 crizotinib PF # 53 multicenter Phase 53 atacicept 53 PROCHYMAL 53 receptor antagonism 53 chronic ITP patients 53 DYNEPO 53 Oncoscience AG 53 leukemia CLL 53 immunoconjugate 53 Silodosin 53 farletuzumab 53 inhalation powder 53 mitotic kinesin 53 SUTENT ® 53 Bicifadine 53 ularitide 53 cardio renal 53 mice overexpressing 53 maytansinoid 53 RDEA# 53 Luveniq 53 HIF PHI 53 ART# 53 immunotherapeutic vaccine 53 Sanvar R 53 NP2 53 E1 INT TM 53 Flt3 53 potent topoisomerase II 53 histone deacetylase HDAC 53 StemEx R 53 IPLEX 53 Zybrestat 53 Xeloda ® 53 anti CD3 53 Vaprisol 53 patientswith 53 Maribavir 53 Fludara ® 53 fluoropyrimidine 53 phase Ib 53 ceftazidime 53 Chemophase 53 Ophena TM 53 Inhaled AAT 53 Tesmilifene 53 MoxDuo 53 rilonacept 53 registrational 53 chronic myocardial ischemia 53 humanized antibody 53 GLPG# 53 enzastaurin 53 tezampanel 53 myeloproliferative disorders 53 Diamyd ® 53 Fibrillex TM 53 PEGPH# 53 Canvaxin TM 53 XmAb# 53 IFN beta 53 ankylosing spondylitis AS 53 Anticalins R 53 Copegus ribavirin 53 SMIP 53 NU# [001] 53 taxane derivative 53 Cethrin 53 Cloretazine R VNP#M 53 ZACTIMA 53 eculizumab 53 orally dosed 53 protein kinase inhibitor 53 HuMax 53 EchoCRT 53 Simulect 53 CTCE 53 TRV# [001] 53 Preclinical studies 53 SU# [003] 53 Phase IIa 53 Fibromyalgia Syndrome 53 potently inhibits 53 Velcade bortezomib 53 Affimed 53 Pazopanib 53 valopicitabine NM# 53 neovascular 53 MB# [004] 53 Epratuzumab 53 LHRH receptor positive 53 microtubule inhibitor 53 TRX4 53 colon carcinoma 53 leading oral taxane 53 beta secretase inhibitor 53 Nexavar ® 53 ara C 53 SCCHN 53 Tanespimycin 53 lomitapide 53 Bosutinib 53 immatics 53 SNT MC# 53 rFVIIIFc 53 M2 subunit 53 rxRNA 53 ZK EPO 53 Akt inhibitor 53 Systemic Sclerosis 53 Moli# 53 interferon beta therapy 53 Uricase PEG 53 Darusentan 53 NeuVax 52 recurrent glioblastoma multiforme 52 Torisel 52 Evoltra R 52 Evoltra 52 K RAS 52 Evoltra ® 52 refractory ovarian cancer 52 NKTR 52 GV# [001] 52 HIV integrase inhibitor 52 BIBW 52 Neulasta ® 52 AACR NCI EORTC 52 IV NSCLC 52 Creabilis Therapeutics 52 Tacrolimus 52 Transthyretin 52 alpha1 proteinase inhibitor 52 Cytochrome P# 52 sodium thiosulfate STS 52 FLT3 52 novel orally bioavailable 52 PF # [001] 52 LEUKINE 52 resminostat 52 TRISENOX 52 PXD# 52 randomized discontinuation trial 52 2DG 52 BMS # 52 NTx TM -# 52 pegylated alpha interferon 52 JenaValve 52 VEGFR2 inhibitor 52 idiopathic thrombocytopenic purpura 52 UVIDEM 52 Inhibitor 52 TKM ApoB 52 tarenflurbil 52 tocilizumab 52 DepoVax 52 GSK# [001] 52 investigational therapies 52 BNC# 52 PAOD 52 Topoisomerase 52 Aptivus ® 52 PARP inhibitor 52 zanolimumab 52 Elitek 52 hypoxia activated prodrug 52 CD# monoclonal antibody 52 relapsed CLL 52 MoxDuo ® 52 endothelin receptor antagonists 52 QRX 52 nitazoxanide 52 investigational compound 52 Angiox R 52 ocrelizumab 52 biliary tract cancer 52 cyclophosphamide methotrexate 52 Dapagliflozin 52 neurogenic orthostatic hypotension 52 Belerofon 52 chronic idiopathic thrombocytopenic purpura 52 CCR1 52 VEGF inhibitor 52 small molecule modulators 52 rhITF 52 prucalopride 52 sapacitabine 52 ON #.Na 52 bispecific 52 Topotecan 52 Pulmonary Arterial Hypertension 52 Xeloda capecitabine 52 relapsing remitting MS RRMS 52 treat hyperphosphatemia 52 huC# DM4 52 AFFiRiS 52 TAXUS Element Paclitaxel Eluting 52 vorinostat 52 IGF 1R inhibitor 52 antithrombotic 52 SGLT2 inhibitor 52 HspE7 52 siRNA therapeutic 52 HCV infected 52 NOD SCID mice 52 acyclovir Lauriad ® 52 OMAPRO 52 recurrent glioma 52 Vascular Wrap TM 52 GA# [003] 52 prostate carcinoma 52 mGluR5 negative 52 Granulocyte Colony Stimulating Factor 52 IMGN# 52 Raf kinase 52 ANTEGREN 52 Teysuno 52 talabostat 52 Junovan TM 52 Systemic Lupus Erythematosus SLE 52 R adalimumab 52 RezularTM 52 NGX# 52 dipeptidyl peptidase IV 52 severe oral mucositis 52 Ocrelizumab 52 Firazyr 52 irreversible inhibitor 52 afamelanotide 52 EOquin TM 52 Apaziquone 52 p# biomarker 52 TLR8 agonist 52 Glufosfamide 52 GCSF 52 IMP# 52 Tavocept 52 Aliskiren 52 intratumoral injection 52 trabedersen 52 Arranon 52 prostate cancer AIPC 52 drug conjugate 52 Cloretazine 52 AMPK activators 52 TBC# 52 cysteamine 52 Octreotide 52 PDX pralatrexate 52 Evoltra TM 52 Sorafenib 52 Bruton tyrosine kinase 52 liposomal delivery 52 ONCONASE 52 3 kinase PI3K 52 OvaRex ® MAb 52 reslizumab 52 Aurora kinase 52 BEMA TM Fentanyl 52 Ixempra 52 phase IIb 52 MEK inhibitors 52 adecatumumab 52 metastatic renal cell 52 Lodotra TM 52 CYC# 52 FOLOTYN ® 52 urocortin 2 52 Solazed 52 haematological cancers 52 SR# [004] 52 syngeneic 52 CD# CD# 52 TREANDA 52 Phase 2a 52 Elagolix 52 histone deacetylase HDAC inhibitors 52 leukemia AML 52 secondary hyperparathyroidism 52 Cytotoxic 52 caspase inhibitor 52 CLORETAZINE TM VNP#M 52 ProLindac 52 Aurora Kinase 52 vemurafenib 52 Interferon beta 52 ProFibrix 52 octreotide 52 refractory multiple myeloma 52 Cinacalcet HCl 52 Anticalin 52 cancer cachexia 52 gefitinib Iressa 52 levodopa induced dyskinesia 52 AP# [003] 52 XL# anticancer compounds 52 Acute Myeloid Leukemia AML 52 IFN alpha 2a 52 masitinib 52 ThGRF 52 PegIFN 52 Panzem 52 Degarelix 52 refractory gout 52 melanocortin receptor agonists 52 MET RET 52 pharmacokinetics PK 52 gastrointestinal stromal tumors GISTs 52 miconazole Lauriad ® 52 BEZ# 52 SGLT2 inhibitors 52 Clolar ® 52 cyclin dependent kinase inhibitor 52 platelet inhibitor 52 Toxicities 52 investigational immunotherapy 52 GRN# 52 PRIALT 52 ARIKACE 52 Pharmacokinetic studies 52 survivin 52 ELND# 52 aurora kinase inhibitor 52 Memryte 52 Revotar 52 Lenalidomide 52 angiotensin receptor blocker ARB 52 platelet aggregation inhibitor 52 IFN α 52 cortisol synthesis 52 Initiates Clinical 52 thrombin receptor 52 Congenital Emphysema 52 GRASPA ® 52 CoFactor 52 Darinaparsin 52 ORENCIA R 52 PLX# 52 Albuferon TM 52 orphan medicinal product 52 LHRH antagonists 52 Neuraltus 52 Dr. Arndt Schottelius 52 radioprotective 52 kinesin spindle protein KSP 52 cytotoxic T lymphocyte 51 Pegasys plus Copegus 51 hypereosinophilic syndrome 51 Clevudine 51 beta lactam 51 sitaxsentan 51 bronchodilatory 51 velafermin 51 Revimmune 51 OvaRex R 51 Phase #/#a trial 51 GALNS 51 T2DM 51 A3 adenosine receptor 51 osteogenic 51 PREOS 51 Multaq dronedarone 51 SHPT 51 Revlimid lenalidomide 51 Hodgkin lymphoma HL 51 topoisomerase II inhibitor 51 Cetrorelix 51 urethral bulking agent 51 Aryplase 51 Rotigotine 51 bevacizumab Avastin ® 51 HuMax CD# 51 Multiple Myeloma MM 51 acetonide FA 51 receptor inhibitor 51 IMC A# 51 bardoxolone 51 COPAXONE R 51 Factor VIIa inhibitor